Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

doi:10.1016/j.msard.2018.07.040

. 2018 Oct:25:173-174.

doi: 10.1016/j.msard.2018.07.040. Epub 2018 Jul 24.

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

Affiliations

¹ Department of Medical Statistics, University Medical Centre Göttingen, Göttingen, Germany.
² MS-Forschungs-und Projektentwicklungs-gGmbH, Hannover, Germany.
³ Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany.
⁴ MS-Center, Jewish Hospital Berlin, Berlin, Germany.
⁵ Department of Neurology, University Hospital Essen, Essen, Germany.
⁶ Department of Neurology, German Red Cross - Kamillus-Clinic, Asbach, Germany.
⁷ Department of Medical Informatics, University Medical Center Göttingen, Germany.
⁸ Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany.
⁹ Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany; Department of Neurology, Medical University of Vienna, Vienna, Austria. Electronic address: Paulus.rommer@meduniwien.ac.at.

PMID: 30096682
DOI: 10.1016/j.msard.2018.07.040

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

David Ellenberger et al. Mult Scler Relat Disord. 2018 Oct.

. 2018 Oct:25:173-174.

doi: 10.1016/j.msard.2018.07.040. Epub 2018 Jul 24.

Authors

Affiliations

¹ Department of Medical Statistics, University Medical Centre Göttingen, Göttingen, Germany.
² MS-Forschungs-und Projektentwicklungs-gGmbH, Hannover, Germany.
³ Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany.
⁴ MS-Center, Jewish Hospital Berlin, Berlin, Germany.
⁵ Department of Neurology, University Hospital Essen, Essen, Germany.
⁶ Department of Neurology, German Red Cross - Kamillus-Clinic, Asbach, Germany.
⁷ Department of Medical Informatics, University Medical Center Göttingen, Germany.
⁸ Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany.
⁹ Department of Neurology, Neuroimmunological Section, University of Rostock, Rostock, Germany; Department of Neurology, Medical University of Vienna, Vienna, Austria. Electronic address: Paulus.rommer@meduniwien.ac.at.

PMID: 30096682
DOI: 10.1016/j.msard.2018.07.040

No abstract available

PubMed Disclaimer

Cited by

Genetic risk variants for multiple sclerosis are linked to differences in alternative pre-mRNA splicing.
Putscher E, Hecker M, Fitzner B, Boxberger N, Schwartz M, Koczan D, Lorenz P, Zettl UK. Putscher E, et al. Front Immunol. 2022 Oct 28;13:931831. doi: 10.3389/fimmu.2022.931831. eCollection 2022. Front Immunol. 2022. PMID: 36405756 Free PMC article.
Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis.
Debus JL, Bachmann P, Frahm N, Mashhadiakbar P, Langhorst SE, Streckenbach B, Baldt J, Heidler F, Hecker M, Zettl UK. Debus JL, et al. Ther Adv Chronic Dis. 2022 Aug 4;13:20406223221108391. doi: 10.1177/20406223221108391. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35959503 Free PMC article.
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)].
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Stangel M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Hunter ZR, Kallmann B, Kleinschnitz C, Klotz L, Leussink V, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber MS, Weber F, Zettl UK, Ziemssen T, Zipp F; die Multiple Sklerose Therapie Konsensus Gruppe (MSTKG). Wiendl H, et al. Nervenarzt. 2021 Aug;92(8):773-801. doi: 10.1007/s00115-021-01157-2. Epub 2021 Jul 23. Nervenarzt. 2021. PMID: 34297142 Free PMC article. Review. German.
Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry.
Ohle LM, Ellenberger D, Flachenecker P, Friede T, Haas J, Hellwig K, Parciak T, Warnke C, Paul F, Zettl UK, Stahmann A. Ohle LM, et al. Sci Rep. 2021 Jun 25;11(1):13340. doi: 10.1038/s41598-021-92722-x. Sci Rep. 2021. PMID: 34172792 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- Genetic Alliance
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

Affiliations

Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis

Authors

Affiliations

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical